The guidance raise and organic growth momentum support the stock, but high net debt ($2B) and integration risk from two acquisitions warrant monitoring. The extended debt maturity profile reduces near-term refinancing risk. Watch for quarterly updates on Breathe Right and LaCorium revenue contribution and deleveraging progress.
Price Chart
Executive Summary
Prestige Consumer Healthcare reported Q1 FY2027 revenue of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98 (+3.2% YoY), exceeding its own expectations and raising full-year guidance. The company closed the Breathe Right and LaCorium acquisitions, adding scale and long-term growth, and extended debt maturities with a $400M senior notes issuance. The guidance raise and organic growth signal improving fundamentals, though GAAP EPS fell to $0.61 due to acquisition-related costs.
Key Financial Metrics
Key Facts
- Q1 FY2027 revenue $265.7M, up 6.5% YoY from $249.5M; organic growth 3.2%
- Adjusted diluted EPS $0.98, up from $0.95 YoY; GAAP diluted EPS $0.61 vs $0.95
- Raised FY2027 guidance: revenue to $1,290-1,315M (from $1,100-1,121M) and adjusted diluted EPS to $4.55-4.65 (from $4.42-4.51)
- Closed Breathe Right (June) and LaCorium Health (July) acquisitions; Breathe Right contributed $5.9M revenue in Q1
- Issued $400M of 6.25% senior notes due 2034, extending nearest debt maturity to 2031; net debt ~$2B
- Operating cash flow $70.8M; adjusted free cash flow $83.7M, up from $78.2M
- GAAP results impacted by ~$22.8M in acquisition-related adjustments including inventory step-up and facility remediation costs
Financial Impact
Revenue raised ~$190M at midpoint vs initial guidance; adjusted EPS raised ~$0.135; acquisitions add ~20% to revenue base
Risk Factors
- Integration of Breathe Right and LaCorium acquisitions may face execution headwinds
- Net debt of ~$2B limits financial flexibility; deleveraging reliant on cash flow
- Clear Eyes supply variability and consumer spending weakness could pressure organic growth
- GAAP EPS decline due to one-time costs may cause short-term noise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340020 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $54.43 $52.56 | ▼ −3.44% | ▼ −4.04% | $45.26 (−16.85%) |
Jul 6, 2026 12w ago | Press Release | $48.86 $50.22 | ▲ +2.78% | ▲ +3.35% | $45.26 (−7.37%) |
Jun 16, 2026 15w ago | 8-K | $47.50 $47.19 | ▼ −0.65% | ▼ −0.85% | $45.26 (−4.72%) |
May 13, 2026 20w ago | 8-K | $45.93 $47.82 | ▼ −4.12% | ▼ −4.97% | $45.26 (+1.46%) |
May 7, 2026 21w ago | 144 | $54.59 $45.44 | ▼ −16.76% | ▼ −19.90% | $45.26 (−17.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access